Large-Cap Biotechs Face Familiar Problem
It looks as if Big Pharma and Big Biotech shares have begun a period of role reversal. Most of the largest drugmakers have seen shares appreciate over the year. That includes notorious laggard Pfizer (PFE), which is up around 5% for 2009. Other Big Pharmas notching solid 2009 stock gains include Roche (RHHBY) (up 12%), Novartis (NVS) (10%), Merck (MRK) (22%), GlaxoSmithKline (GSK) (13%), Bristol-Myers-Squibb (BMY) (11%) and Sanofi-Aventis (SNY)
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here